• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Beating Inflation With Biotech

Biotech and pharma companies have the biggest edge in pricing power.
By JOHN REESE
Mar 13, 2012 | 07:30 AM EDT
Stocks quotes in this article: BIIB, SLXP, QCOR

Keep ahead of inflation and you can do very well, whether it is return on investments if you are an individual investor or what you charge if you are a business owner. Raise your prices faster than inflation and your bottom line can become fat and happy.

The trick is being able to outrun inflation. Investors in the past dozen years learned first hand how hard this is and many businesses have also found it tough. Many, but not all.

If inflation were Wile E. Coyote then its Road Runner might well be the pharmaceutical industry. An AARP study found that of drugs used most by older Americans, prices rose nearly 26% from 2005 to 2009, which was close to twice the inflation rate.

National Public Radio reported January that the "biggest (drug) companies raised list prices for brand-name drugs an average of 4.5% this month, when new prices typically kick in. Back in January 2008, the same companies raised prices an average of 2.8%." Inflation now runs at 3.4%, NPR said.

The New York Times reports that in 1992 Bristol-Myers Squibb (BMY) faced opposition to its pricing of Taxol, a breast-cancer treatment, at $4,000 a year. Now, the price of most new cancer treatments us in the stratosphere of $25,000 to $50,000 annually.

The Times article goes on to note that when a drug does not face any competition, "its maker can charge almost any price (and) once a company sets a price, government agencies, private insurers and patients have little choice but to pay it."

Nice. Wouldn't we all like such pricing leverage? We can by investing in pharmaceutical companies and riding their pricing power. Questcor (QCOR) is a biopharmaceutical. It has one drug on the market, Acthar, which is used for multiple sclerosis and nephritic syndrome, a rare kidney disease, as well as other indications.

Admittedly an investment in Questcor is a gamble, but risk-taking investors should pay it some attention. An analysis by my Martin Zweig-based strategy, which I modeled on Zweig's description of his approach to investing, likes Questcor because both its revenues and earnings are growing in tandem (the strategy does not want to see earnings growth far outpace revenue growth), earnings growth for the past several quarters is up and the company has no debt.

A company with two multiple sclerosis drugs is Biogen Idec (BIIB), which also has a cancer drug. A computerized strategy I created from Peter Lynch's writings likes this company, particularly because of its P/E/G (price-to-earnings relative to growth) ratio. A measure of how much the investor is paying for growth, the P/E/G ratio cannot be greater than 1.0. Biogen Idec's is 0.71. Also in the company's favor is its modest amount of debt.

Another company earning accolades from the Lynch strategy is Salix Pharmaceuticals (SLXP), which addresses the gastroenterology market. Salix's P/E/G is 0.81. But it does have more debt than either Questcor or Biogen Idec.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, the author and his clients were long QCOR and BIIB.

TAGS: Investing | U.S. Equity | Healthcare |

More from Healthcare

A Pullback in TG Therapeutics Looks Like a Buying Opportunity

Bruce Kamich
Jun 8, 2023 8:30 AM EDT

The charts of the biopharmaceutical company are telling a largely bullish story.

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login